Walter V. Klemp - Nov 12, 2025 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
CEO and President, Director
Signature
/s/ Jonathan P. Foster by Power of Attorney
Stock symbol
MBRX
Transactions as of
Nov 12, 2025
Transactions value $
$0
Form type
4
Date filed
11/14/2025, 04:07 PM
Previous filing
Nov 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KLEMP WALTER V CEO and President, Director C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON /s/ Jonathan P. Foster by Power of Attorney 2025-11-14 0000938419

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Stock option (right to buy) Award +830K +34.86% 3.21M Nov 12, 2025 Common Stock 830K $0.49 Direct F1, F2
transaction MBRX Performance Based Restricted Stock Units Award +750K +23.36% 3.96M Nov 12, 2025 Common Stock 750K Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
F2 Issued in connection with the reporting person's employment with the Company.
F3 Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
F4 On November 12, 2025, the Board approved this performance based restricted stock unit. The performance based restricted stock units set forth in this table will vest in 20% installments upon the achievement of certain clinical milestones; provided that upon a change of control (as defined in the 2024 Stock Plan) 100% shall vest.